Peptide-based inhibition of CD44v6 renders liver carcinomas more susceptible to therapeutic intervention.

ABSTRACT: Cluster of differentiation 44 variant 6 (CD44v6) has been described in various types of cancer, including liver cancer. Despite significant advancements in cancer therapy, there is still an urgent medical need for new therapeutic strategies for the treatment of liver tumours that are efficacious but well tolerated. One promising approach involves the use of small molecules, such as peptides, which intervene in central signalling pathways to prevent the migration of cancer cells and their invasion into other organs without affecting other cell types. We analysed the expression of CD44v6 in human cirrhotic livers, liver tumour tissues and organoids as well as in preclinical models of chronic liver disease and subsequent liver tumour formation. We overexpressed CD44v6 in CD44v6-negative cell

SUBMITTER: Srikanth A 

PROVIDER: S-EPMC12675676 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature